Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Dongwha Pharm Co., Ltd. is a leading South Korean pharmaceutical company specializing in the development and production of generic and specialty drugs, particularly in the fields of oncology and cardiovascular health. The company's competitive position is strengthened by its extensive R&D capabilities and a robust portfolio of patented drugs, primarily serving the domestic market and expanding into international markets.
Dongwha Pharm generates revenue primarily through the sale of generic and specialty pharmaceuticals, leveraging its strong R&D capabilities to develop cost-effective alternatives to branded drugs. The company benefits from pricing power in the generic market due to its established relationships with healthcare providers and a growing demand for affordable medications.
Approval of new drug applications by the Korean FDA
Market expansion into Southeast Asia and other international markets
Changes in healthcare regulations affecting drug pricing
Fluctuations in raw material costs impacting production expenses
Regulatory changes that could impact drug approval processes or pricing structures
Technological disruption in drug development or manufacturing processes
Intensifying competition from both domestic and international generic drug manufacturers
Potential loss of patent protection on key products
Negative free cash flow of $37.5B could limit future investments
Potential liquidity risks if operating cash flow does not improve
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand for non-essential drugs can be affected by consumer spending.
Interest rates impact Dongwha Pharm's financing costs for R&D and capital expenditures, which could affect its growth strategy and valuation multiples.
minimal - The company maintains a low debt-to-equity ratio of 0.32, indicating limited reliance on external financing.
value - Investors may be drawn to the stock due to its low valuation metrics (P/S of 0.3x, P/B of 0.4x) and potential for recovery as margins improve.
moderate - The stock has shown volatility with a 1-year return of -22.0%, reflecting market sensitivity to regulatory and competitive pressures.
